Denis Drygin Biography and Net Worth

Insider of Regulus Therapeutics

Dr. Drygin joined Regulus in August 2020 and currently serves as Chief Scientific Officer. Prior to joining Regulus, Dr. Drygin served as Vice President of Research & Development for Pimera Inc., a privately held biopharmaceutical company of which Dr. Drygin is a Founder. Before Pimera, Dr. Drygin was with Cylene Pharmaceuticals, most recently serving as Vice President of Biology. With nearly 20 years of experience, Dr. Drygin led discovery and/or development of multiple therapeutics including first selective inhibitor of CK2 kinase Silmitasertib (CX-4945), first selective inhibitor of RNA Polymerase I transcription (Pol I) CX-5461, as well as second generation Pol I inhibitor PMR-116. Dr. Drygin has authored more than 80 book chapters, reviews, manuscripts, abstracts, and patent applications. He received his BS/MS in Chemistry from Moscow State University, MS/PhD in Molecular and Cellular Biology from University of Massachusetts at Amherst and Post-Doctoral training in Pharmacology and Toxicology from Ionis Pharmaceuticals.

How do I contact Denis Drygin?: The corporate mailing address for Dr. Drygin and other Regulus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Regulus Therapeutics can also be reached via phone at (858) 202-6300 and via email at [email protected]. Learn More on Denis Drygin's contact information.
Has Denis Drygin been buying or selling shares of Regulus Therapeutics?: Denis Drygin has not been actively trading shares of Regulus Therapeutics within the last three months. Most recently, on Friday, February 4th, Denis Drygin bought 23,314 shares of Regulus Therapeutics stock. The stock was acquired at an average cost of $0.23 per share, with a total value of $5,362.22. Learn More on Denis Drygin's trading history.
Who are Regulus Therapeutics' active insiders?: Regulus Therapeutics' insider roster includes Christopher Aker (VP), Denis Drygin (Insider), and Joseph Hagan (CEO). Learn More on Regulus Therapeutics' active insiders.
Are insiders buying or selling shares of Regulus Therapeutics?: During the last twelve months, Regulus Therapeutics insiders bought shares 1 times. They purchased a total of 4,000 shares worth more than $7,280.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 20,048 shares worth more than $23,857.12. The most recent insider tranaction occured on July, 25th when Director Kathryn J Collier bought 4,000 shares worth more than $7,280.00. Insiders at Regulus Therapeutics own 4.4% of the company. Learn More about insider trades at Regulus Therapeutics.
Information on this page was last updated on 7/25/2024.

Denis Drygin Insider Trading History at Regulus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/4/2022	Buy	23,314	$0.23	$5,362.22

Denis Drygin Buying and Selling Activity at Regulus Therapeutics

Regulus Therapeutics Company Overview

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $1.59

$1.51

$1.60

50 Day Range

MA: $1.53

$1.40

$1.70

2 Week Range

Now: $1.59

$1.08

$3.79

Volume

462,262 shs

Average Volume

1,154,690 shs

Market Capitalization

$104.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.